IPG-CETIRIZINE TABLET

Țară: Canada

Limbă: engleză

Sursă: Health Canada

Cumpara asta acum

Ingredient activ:

CETIRIZINE HYDROCHLORIDE

Disponibil de la:

MARCAN PHARMACEUTICALS INC

Codul ATC:

R06AE07

INN (nume internaţional):

CETIRIZINE

Dozare:

10MG

Forma farmaceutică:

TABLET

Compoziție:

CETIRIZINE HYDROCHLORIDE 10MG

Calea de administrare:

ORAL

Unități în pachet:

30/100/500

Tip de prescriptie medicala:

OTC

Zonă Terapeutică:

SECOND GENERATION ANTIHISTAMINES

Rezumat produs:

Active ingredient group (AIG) number: 0122686001; AHFS:

Statutul autorizaţiei:

APPROVED

Data de autorizare:

2016-06-29

Caracteristicilor produsului

                                IPG-CETIRIZINE - Product Monograph
Page 1 of 34
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
IPG-CETIRIZINE
Cetirizine Hydrochloride Tablets
Tablets, 5 mg, 10 mg, Oral
Histamine H
1
Receptor Antagonist
Marcan Pharmaceuticals Inc.
2 Gurdwara Road, Suite #112
Ottawa, ON, K2E 1A2
Date of Initial Authorization:
JUN 06, 2014
Date of Revision:
JAN 24, 2023
Submission Control Number: 267528
IPG-CETIRIZINE - Product Monograph
Page 2 of 34
RECENT MAJOR LABEL CHANGES
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
.............................................................................................2
TABLE OF CONTENTS
...............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
...............................................................................................................4
1.1
Pediatrics
...........................................................................................................4
1.2
Geriatrics............................................................................................................4
2
CONTRAINDICATIONS
..................................................................................................4
4
DOSAGE AND ADMINISTRATION
..................................................................................4
4.1
Dosing
Considerations.........................................................................................4
4.2
Recommended Dose and Dosage
Adjustment......................................................4
4.4
Administration....................................................................................................5
4.5
Missed Dose
.......................................................................................................5
5
OVERDOSAGE
...............
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Caracteristicilor produsului Caracteristicilor produsului franceză 24-01-2023

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor